9-Me-BC (9-Methyl-β-carboline)

9-Me-BC (9-Methyl-β-carboline) at a Glance

9-Me-BC (9-methyl-β-carboline) is a small β-carboline alkaloid — the β-carboline scaffold is the tryptophan-derived ring system also found in harmine and harmaline — carrying a single methyl group on its indole nitrogen. It is studied almost entirely as a laboratory tool for one striking property: in cell cultures and in a rat model of Parkinson’s disease, it stimulates, protects and partially regenerates dopamine-producing neurons.

It has no meaningful role as a food component or nutrient. β-carbolines as a class form endogenously and turn up in trace amounts in cooked meat, coffee, alcohol and tobacco smoke, but 9-Me-BC is not something you obtain from the diet — it is synthesised in the lab, and the material sold to consumers is a research chemical, not an approved supplement or medicine.

There is no deficiency of 9-Me-BC to correct. Every reported effect is an extra pharmacological action layered onto a normal nervous system, and every one of those effects has been seen only in rodents or cultured cells. There are no human trials of any kind — not for Parkinson’s disease, not for cognition, not for safety. The preclinical dossier is genuinely interesting and internally consistent, but it sits entirely on the animal and cell side of the translation gap, and it carries real, uncharacterised risks: monoamine-oxidase inhibition, a potentially neurotoxic metabolite, and DNA-damaging photochemistry.

What It’s Used For

There is no approved or clinically validated use for 9-Me-BC. The items below are research directions and the informal reasons it is sold as a nootropic, ranked by how well the preclinical evidence holds up.

• Parkinson’s disease & dopaminergic neuroprotection — restores dopamine-neuron counts and function in a rat toxin model and in culture. The strongest strand, but animal- and cell-only, and in the key in-vivo study the compound was infused directly into the brain.
• Cognitive enhancement — a single rat study improved spatial learning alongside higher hippocampal dopamine and more dendritic spines. One study, one species; the whole nootropic reputation rests on it.
• Neurotrophic & anti-inflammatory support — induces BDNF and related growth factors and calms activated microglia in vitro. A plausible mechanism, demonstrated only in cell culture.

Be sceptical of any claim that 9-Me-BC is a proven human dopamine booster, an anti-ageing or brain-regenerating supplement, or a safe daily nootropic. The human efficacy and safety record is simply empty — and the MAO-inhibiting activity means it is not pharmacologically inert.

How It Works

9-Me-BC is a β-carboline, one of a family of pyridoindole alkaloids built from tryptophan. Most β-carbolines are studied as potential neurotoxins; 9-Me-BC is the unusual member that showed the opposite — stimulatory and protective effects on dopaminergic neurons. Its actions cluster into a few linked mechanisms rather than a single receptor.

The core effect is on the machinery that makes and maintains dopamine neurons. In primary midbrain cultures 9-Me-BC raises the number of neurons expressing tyrosine hydroxylase — the rate-limiting enzyme for dopamine synthesis — and switches on a suite of transcription factors and neurotrophic genes, among them Nurr1, Pitx3, Wnt and Shh signalling, and later BDNF, that normally drive dopaminergic differentiation and survival ^{1,2Reference 1Hamann J et al. · 2008In vitroHamann J, Wernicke C, Lehmann J, et al. (2008). 9-Methyl-β-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture — in vitro. Neurochemistry International. https://pubmed.ncbi.nlm.nih.gov/17913302/View study →Reference 2Polanski W et al. · 2010In vitroThe exceptional properties of 9-methyl-β-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects — in vitroView study →}. In parallel it promotes neurite outgrowth and, in astrocytes, induces neurotrophic factors through the PI3-kinase pathway ^{5Reference 5Keller S et al. · 2020In vitroKeller S, Polanski WH, Enzensperger C, et al. (2020). 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes — in vitro. Journal of Neural Transmission. https://pubmed.ncbi.nlm.nih.gov/32285253/View study →}. It also curbs microglial proliferation and inflammatory cytokines, and lowers levels of α-synuclein, the protein that aggregates in Parkinson’s disease ^{2Reference 2Polanski W et al. · 2010In vitroThe exceptional properties of 9-methyl-β-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects — in vitroView study →}.

A second, separate mechanism is monoamine-oxidase inhibition. 9-Me-BC inhibits MAO-A and, more weakly, MAO-B ^{5,7Reference 5Keller S et al. · 2020In vitroKeller S, Polanski WH, Enzensperger C, et al. (2020). 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes — in vitro. Journal of Neural Transmission. https://pubmed.ncbi.nlm.nih.gov/32285253/View study →Reference 7Herraiz T · 2011In vitroInhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors — in vitroView study →}. MAO is the enzyme that breaks down dopamine, serotonin and noradrenaline, so inhibiting it raises the standing level of these transmitters — a likely contributor to the higher dopamine content seen in treated cultures and rat brain. This is the same mechanism that makes classical MAO inhibitors effective antidepressants and dangerous alongside serotonergic drugs and tyramine-rich foods, and it is the single most important pharmacological flag here.

Two wrinkles temper the enthusiasm. First, the most convincing in-vivo result was produced by infusing 9-Me-BC directly into a rat’s cerebral ventricle ^{3Reference 3Wernicke C et al. · 2010AnimalWernicke C, Hellmann J, Zieba B, et al. (2010). 9-Methyl-β-carboline has restorative effects in an animal model of Parkinson’s disease — rat, in vivo. Pharmacological Reports. https://pubmed.ncbi.nlm.nih.gov/20360614/View study →}, bypassing the gut, liver and blood-brain barrier entirely — so it says little about what an oral dose would do. Second, β-carbolines can be N-methylated a second time in the body to charged 2,9-dimethyl-β-carbolinium cations that are structural cousins of the classic Parkinsonian toxin MPP+ ^{8Reference 8Gearhart DA et al. · 2002In vitroPhenylethanolamine N-methyltransferase has β-carboline 2N-methyltransferase activity: hypothetical relevance to Parkinson’s disease — in vitroView study →} — a metabolic route that turns the good molecule into a potentially bad one, and one reason the neurotoxin-versus-neuroprotectant story in this family is genuinely unsettled.

Pharmacology & Research

9-Me-BC is a β-carboline alkaloid investigated as a candidate disease-modifying agent for Parkinson’s disease and, secondarily, as a cognitive enhancer. The overall evidence posture is preclinical only: a coherent and repeatedly reproduced picture of dopaminergic stimulation, neuroprotection, regeneration and anti-inflammatory action across primary cultures and one rat toxin model, published mainly by a single German research group. There is no deficiency state to correct — every effect is a pharmacological extra on a normal system — and there are no human pharmacokinetic, efficacy or safety data. A major translational caveat is route of delivery: the pivotal in-vivo study used intracerebroventricular infusion, not oral dosing, so oral bioavailability and brain exposure in humans are unknown.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Because 9-Me-BC has no human data at all, every score here sits in the lowest, preclinical band by design. Each application links down to its write-up.

01Parkinson’s disease & dopaminergic neuroprotectionShaky24%One rat toxin model (intracerebroventricular) plus repeated primary-culture work; no human data

02Cognitive enhancementShaky16%A single rat radial-maze study; no human data

03Neurotrophic & anti-inflammatory supportShaky12%In-vitro culture only — mesencephalic neurons, astrocytes, microglia

Mechanisms

Pharmacokinetics

There are no human pharmacokinetic data for 9-Me-BC — no measured oral bioavailability, plasma or brain concentrations, metabolism profile, or half-life. This is the decision-relevant gap: the most convincing efficacy result was obtained by infusing the compound directly into rat brain ventricles ^{3Reference 3Wernicke C et al. · 2010AnimalWernicke C, Hellmann J, Zieba B, et al. (2010). 9-Methyl-β-carboline has restorative effects in an animal model of Parkinson’s disease — rat, in vivo. Pharmacological Reports. https://pubmed.ncbi.nlm.nih.gov/20360614/View study →}, deliberately bypassing gastrointestinal absorption, first-pass liver metabolism and the blood-brain barrier, so it provides no guidance on what an oral dose reaches the brain in a person. Mechanistically, β-carbolines are lipophilic small molecules that can cross the blood-brain barrier and are subject to further N-methylation in the body; 9-Me-BC is a known substrate for a brain 2N-methyltransferase that converts it to a charged, MPP+-like cation ^{8Reference 8Gearhart DA et al. · 2002In vitroPhenylethanolamine N-methyltransferase has β-carboline 2N-methyltransferase activity: hypothetical relevance to Parkinson’s disease — in vitroView study →}. Any oral human dose would therefore face uncharacterised absorption, uncharacterised metabolism, and a plausible route to a neurotoxic metabolite.

Clinical trials

There is no registered clinical-trial activity for 9-Me-BC. A search of ClinicalTrials.gov returns zero studies, and there are no completed or ongoing human trials in the literature. All research is preclinical, and with no patent-driven industry programme behind it there is little sign of imminent clinical development beyond its status as a proposed drug candidate in review articles ^{6Reference 6Polanski W et al. · 2011ReviewStimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug? — reviewView study →}.

Last checked: August 2026.

Dietary Sources

9-Me-BC is not a dietary nutrient, so there is no food that supplies it in a meaningful way and nothing to replace. β-carbolines as a class occur endogenously — in blood, brain and cerebrospinal fluid — and appear in trace amounts in cooked and processed foods, including cooked meat, coffee, alcohol and tobacco smoke ^{1,4Reference 1Hamann J et al. · 2008In vitroHamann J, Wernicke C, Lehmann J, et al. (2008). 9-Methyl-β-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture — in vitro. Neurochemistry International. https://pubmed.ncbi.nlm.nih.gov/17913302/View study →Reference 4Gruss M et al. · 2012AnimalGruss M, Appenroth D, Flubacher A, et al. (2012). 9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation — rat, in vivo. Journal of Neurochemistry. https://pubmed.ncbi.nlm.nih.gov/22380576/View study →}. However, these dietary β-carbolines are predominantly the unmethylated or differently substituted members of the family, such as norharman and harman, several of which are studied as potential neurotoxins rather than as beneficial compounds. The specific 9-methyl derivative used in research is prepared synthetically. Dietary exposure to β-carbolines is real but incidental, and the material sold to consumers is a laboratory-synthesised research chemical.

Dosage

There is no established or validated human dose of 9-Me-BC, and none is given here. It is not an approved supplement or medicine, and no human study has ever tested a dose for efficacy or safety. Any figures circulating online are extrapolations from rodent experiments — several of which delivered the compound directly into the brain rather than by mouth ^{3,4Reference 3Wernicke C et al. · 2010AnimalWernicke C, Hellmann J, Zieba B, et al. (2010). 9-Methyl-β-carboline has restorative effects in an animal model of Parkinson’s disease — rat, in vivo. Pharmacological Reports. https://pubmed.ncbi.nlm.nih.gov/20360614/View study →Reference 4Gruss M et al. · 2012AnimalGruss M, Appenroth D, Flubacher A, et al. (2012). 9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation — rat, in vivo. Journal of Neurochemistry. https://pubmed.ncbi.nlm.nih.gov/22380576/View study →} — and animal doses do not translate to safe or effective human doses. Because the compound inhibits monoamine oxidase ^{5,7Reference 5Keller S et al. · 2020In vitroKeller S, Polanski WH, Enzensperger C, et al. (2020). 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes — in vitro. Journal of Neural Transmission. https://pubmed.ncbi.nlm.nih.gov/32285253/View study →Reference 7Herraiz T · 2011In vitroInhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors — in vitroView study →} and has a plausible route to a neurotoxic metabolite ^{8Reference 8Gearhart DA et al. · 2002In vitroPhenylethanolamine N-methyltransferase has β-carboline 2N-methyltransferase activity: hypothetical relevance to Parkinson’s disease — in vitroView study →}, self-experimentation carries specific, uncharacterised risks. The responsible reading of the current evidence is that 9-Me-BC is not ready for human use.

Safety

9-Me-BC’s safety profile in humans is unstudied, not established as clean. It is a research chemical with no human toxicity, tolerability or pregnancy data, and the preclinical record flags several specific hazards rather than offering reassurance.

Safety at a Glance

⚠️ Moderate toxicityDrug interactionsSerotonin riskResearch compound

• Not an approved supplement or drug. 9-Me-BC is a research chemical with no human safety testing; toxicity, tolerated dose and long-term effects are all uncharacterised.
• Monoamine-oxidase inhibition is a real interaction risk. It inhibits MAO-A and MAO-B, the mechanism behind dangerous MAOI interactions with serotonergic drugs, other MAOIs, stimulants and tyramine-rich foods.
• Potential neurotoxic metabolite. β-carbolines can be N-methylated to 2,9-dimethyl-β-carbolinium cations structurally akin to the Parkinsonian toxin MPP+.
• DNA-damaging under UV light in vitro. 9-methyl-β-carbolines are efficient photosensitisers that cause oxidative DNA damage and strand breaks upon UVA excitation in laboratory studies.
• No pregnancy, lactation or paediatric data. Reproductive and developmental safety have not been assessed.

Full Safety & Interactions Detail

No human adverse-effect data exist, because 9-Me-BC has never been administered to people in a documented study. The defining risks are therefore inferred from pharmacology and preclinical chemistry rather than measured.

The clearest interaction concern is monoamine-oxidase inhibition. 9-Me-BC inhibits MAO-A with an IC₅₀ around 1 µM and MAO-B around 15.5 µM in vitro ^{5Reference 5Keller S et al. · 2020In vitroKeller S, Polanski WH, Enzensperger C, et al. (2020). 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes — in vitro. Journal of Neural Transmission. https://pubmed.ncbi.nlm.nih.gov/32285253/View study →}, and related work confirms MAO-B inhibition and blockade of MPTP bioactivation ^{7Reference 7Herraiz T · 2011In vitroInhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors — in vitroView study →}.

Clinically, MAO inhibitors interact dangerously with serotonergic antidepressants, other MAO inhibitors, triptans, tramadol and dextromethorphan (risk of serotonin syndrome); with sympathomimetic stimulants (hypertensive crisis); and with tyramine-rich foods such as aged cheese, cured meats and fermented products. None of this has been quantified for 9-Me-BC in humans, but the mechanism is established and should be treated as a genuine flag, especially for anyone on psychiatric medication.

A second, more theoretical hazard is metabolic: β-carbolines can undergo 2N-methylation to charged β-carbolinium cations that are structural and functional analogues of MPP+, the toxin used to model Parkinson’s disease ^{8Reference 8Gearhart DA et al. · 2002In vitroPhenylethanolamine N-methyltransferase has β-carboline 2N-methyltransferase activity: hypothetical relevance to Parkinson’s disease — in vitroView study →}.

The same family that yields the “neuroprotective” 9-Me-BC can therefore also yield neurotoxic species, and the balance in a living human is unknown. Third, the 9-methyl-β-carbolines are efficient photosensitisers: under UVA light at physiological pH they generate oxidative DNA damage, single-strand breaks and pyrimidine dimers in vitro ^{9Reference 9Vignoni M et al. · 2013In vitroMechanisms of DNA damage by photoexcited 9-methyl-β-carbolines — in vitroView study →} — a genotoxicity signal whose in-vivo relevance is untested.

Who should be especially cautious. Anyone taking antidepressants or other serotonergic or MAOI drugs, anyone with cardiovascular disease, pregnant or breastfeeding people, and anyone unwilling to accept an entirely unquantified risk. Given the absence of human data, no safe population can actually be identified.

Scope disclosure. Interactions assessed? Yes — MAO substrates and inhibitors, serotonergic agents, sympathomimetic stimulants and tyramine-containing foods, all on a mechanistic basis only. Pregnancy/lactation assessed? No human or animal reproductive data located. Upper limit established? No — no human dose or tolerated upper limit exists.

Pregnancy & Lactation

⚠ Avoid in pregnancy⚠ Avoid while breastfeeding

Avoid. No reproductive-toxicity, developmental or human pregnancy data exist for 9-Me-BC, and it is an untested research chemical with MAO-inhibiting activity and a plausible neurotoxic metabolite. In the absence of any safety information, and given the known sensitivity of the developing nervous system to β-carbolines and to MAO inhibition, it should not be used during pregnancy or breastfeeding.

References

1. Hamann J, Wernicke C, Lehmann J, et al. (2008). 9-Methyl-β-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture — in vitro. Neurochemistry International. https://pubmed.ncbi.nlm.nih.gov/17913302/
2. Polanski W, Enzensperger C, Reichmann H, et al. (2010). The exceptional properties of 9-methyl-β-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects — in vitro. Journal of Neurochemistry. https://pubmed.ncbi.nlm.nih.gov/20374418/
3. Wernicke C, Hellmann J, Zieba B, et al. (2010). 9-Methyl-β-carboline has restorative effects in an animal model of Parkinson’s disease — rat, in vivo. Pharmacological Reports. https://pubmed.ncbi.nlm.nih.gov/20360614/
4. Gruss M, Appenroth D, Flubacher A, et al. (2012). 9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation — rat, in vivo. Journal of Neurochemistry. https://pubmed.ncbi.nlm.nih.gov/22380576/
5. Keller S, Polanski WH, Enzensperger C, et al. (2020). 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes — in vitro. Journal of Neural Transmission. https://pubmed.ncbi.nlm.nih.gov/32285253/
6. Polanski W, Reichmann H, Gille G (2011). Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug? — review. Expert Review of Neurotherapeutics. https://pubmed.ncbi.nlm.nih.gov/21651332/
7. Herraiz T, Guillén H (2011). Inhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors — in vitro. Food and Chemical Toxicology. https://pubmed.ncbi.nlm.nih.gov/21554916/
8. Gearhart DA, Neafsey EJ, Collins MA (2002). Phenylethanolamine N-methyltransferase has β-carboline 2N-methyltransferase activity: hypothetical relevance to Parkinson’s disease — in vitro. Neurochemistry International. https://pubmed.ncbi.nlm.nih.gov/11900856/
9. Vignoni M, Rasse-Suriani FA, Butzbach K, et al. (2013). Mechanisms of DNA damage by photoexcited 9-methyl-β-carbolines — in vitro. Organic & Biomolecular Chemistry. https://pubmed.ncbi.nlm.nih.gov/23842892/

View all 9 references▾